Skip to main content
Equibles

ADVENZYMES · Advanced Enzyme Technologies Limited

Use ADVENZYMES with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADVENZYMES.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
283.60 INR -0.50 (-0.18%) At close · Nov 13
Rebalance outlook locked
Market Cap
31.52B INR
Shares
111.15M
Volume · Nov 13 118.61K Avg daily vol (3M) 226.35K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close283.60 INR Open281.25 INR Day280.70–285.15 INR 52W close248.35–392.10 INR Avg vol 30d233K Last earningsNov 3, 2026 DataJan 2020–Nov 2026

Latest documents

2026
Nov 3
Earnings call
Q2 FY27 revenue rises 16%, EBITDA 20%, PAT 14%

Advanced Enzyme Technologies Limited reported Q2 FY27 revenue of INR2,145 million, up 16% year-on-year, EBITDA of INR721 million, up 20%, and PAT of INR512 million, up 14%; management targets 30% to 32% EBITDA margins.

5 source passages
Advanced Enzyme Technologies Limited Q2 and H1 FY27 Earnings Conference Call. Our top line for the quarter stood at INR2,145 million, registering a growth of 16% year-on-year and 12% on a sequential basis, while the first half of financial year '27 revenue grew by 10% over the corresponding period last year. EBITDA increased to INR721 crores, up 20% year-on-year and 36% sequentially, while the same grew by 7% on a year-to-date basis. Profit after tax, PAT, stood at INR512 million, grew by 14% year-onyear basis, 33% sequential basis and 5% on a YTD basis. So we are saying that as of now, for calculation purpose, we are going with 30% to 32% of EBITDA level. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲5.1% 1.69B INR 376.47M INR '25 Q3 ▲5.9% 1.67B INR 264.82M INR '25 Q4 ▲20.3% 1.86B INR 399.30M INR '26 Q1 ▲26.3% 1.85B INR 433.26M INR '26 Q2 ▲1.7% 1.72B INR 425.00M INR '26 Q3 ▲21.6% 2.03B INR 429.63M INR '26 Q4 ▲2.1% 1.90B INR 370.93M INR '27 Q1 LATEST ▲16.2% 2.15B INR 483.06M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 248.35 INR Now 283.60 INR · 25% Range high 392.10 INR
vs 200-day avg -8% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XNSE:ADVENZYMES +1.2% +7.9% -24.4% +7.6% -6.2%

Exchange listing

Market
XNSE
Ticker
ADVENZYMES
ISIN
INE837H01020
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.advancedenzymes.com/
Investor relations
https://www.advancedenzymes.com/investors/quarterly-updates/financial-results/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-07-24 1.35 INR
2025-07-23 1.20 INR
2025-05-16 4.00 INR
2024-07-18 1.10 INR
2024-05-17 4.00 INR
2023-08-04 1.00 INR
2023-05-19 4.00 INR
2022-08-11 1.00 INR
2021-08-31 0.90 INR
2020-07-09 0.60 INR
2019-08-01 0.60 INR
2018-09-06 0.50 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-03 Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-08-12 Transcript
    Earnings Call for the Quarter Ended June 30, 2026
  • Earnings call · Q4 2026 2026-05-12
    Earnings Call for the Quarter Ended March 31, 2026